ReviewClinical endocrinology2022
Challenges in diagnosis and understanding of natural history of polycystic ovary syndrome.
Review in Clinical endocrinology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed.
- Metabolic and Anti-Inflammatory Effects of Berberine-Rationale for Its Therapeutic Potential in Polycystic Ovary Syndrome.International journal of molecular sciences · 2026Review
- Retinoic acid disrupts cumulus granulosa cells function via EGFR downregulation: induction of PCOS and infertility in adult female mice.Histochemistry and cell biology · 2026Article
- Natural Bioactive Compounds in Polycystic Ovary Syndrome: Properties, Molecular Mechanisms, and Therapeutic Potential.International journal of molecular sciences · 2026Review
- Oxidative stress and the therapeutic potential of dietary antioxidants in polycystic ovary syndrome: a narrative review.Journal of ovarian research · 2026Review
- The Stimulating Effect of Low-Molecular-Weight Luteinizing Hormone Receptor Agonist on Steroidogenesis and Ovulation in Female Rats with Dehydroepiandrosterone-Induced Polycystic Ovary Syndrome.International journal of molecular sciences · 2026Article
- Combined metabolic-reproductive association and predictive value of AMH and TyG index in PCOS: a single-center retrospective study.Frontiers in endocrinology · 2026Article
- Astaxanthin as a potential therapeutic agent in polycystic ovary syndrome: a review of its antioxidant, anti-inflammatory, and metabolic mechanisms.Frontiers in reproductive health · 2026Review
- Extended Letrozole Treatment for Ovulation Induction and Clinical Pregnancy in Conventional Treatment-resistant Polycystic Ovary Syndrome Patients: A Prospective Parallel Randomized Clinical Trial.Journal of obstetrics and gynaecology of India · 2025Article
- Multi-specialty Physician Preferences and Perceptions in Treatment and Management of Polycystic Ovary Syndrome in China: Survey and Discrete Choice Experiment.Advances in therapy · 2025Article
- Risk Factors for Hypertension in Polycystic Ovary Syndrome: Evidence from a Retrospective Study.Life (Basel, Switzerland) · 2025Article
- The PCOS Phenotypes in Unselected Populations (P-PUP) study: participant clinical features and data harmonization on analysis of individual participant data.BMC medicine · 2025Article
- Harnessing Microbiome, Bacterial Extracellular Vesicle, and Artificial Intelligence for Polycystic Ovary Syndrome Diagnosis and Management.Biomolecules · 2025Review
- Metformin use in women with polycystic ovary syndrome (PCOS): Opportunities, benefits, and clinical challenges.Diabetes, obesity & metabolism · 2025Review
- Review
- Effect and mechanism of resveratrol against polycystic ovary syndrome: a review.Frontiers in endocrinology · 2025Review
- Development and validation of an explainable machine learning and nomogram model for early detection and risk stratification of polycystic ovary syndrome: a multicenter study.Frontiers in endocrinology · 2025Article
- A sustainable public health framework for PCOS management in low- and middle-income countries: a narrative review.Frontiers in reproductive health · 2025Review
- Women with PCOS have a heightened risk of cardiometabolic and cardiovascular diseases: statement from the Experts Group on Inositol in Basic and Clinical Research and PCOS (EGOI-PCOS) and Italian Association of Hospital Cardiologists (ANMCO).Frontiers in cardiovascular medicine · 2025Review
- Polycystic Ovary Syndrome: A Comprehensive Exploration of Diagnosis Experience in Saudi Women.Journal of clinical medicine · 2024Article
- Stanniocalcin Protein Expression in Female Reproductive Organs: Literature Review and Public Cancer Database Analysis.Endocrinology · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Polycystic ovary syndrome (PCOS) is the most common endocrinopathy affecting 8%-13% of reproductive-aged women. The aetiology of the syndrome is complex, with genetic susceptibility, androgen exposure in early life and adiposity related dysfunction leading to perturbance in hypothalamic-ovarian function. PCOS clinical features are heterogeneous, with manifestations arising even in early adolescence, developing into multisystem reproductive, metabolic and psychological manifestations in adulthood. In this review, we will discuss challenges in the diagnosis of PCOS and understanding of the natural history of PCOS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.